Evaluation of Galcanezumab in the Prevention of Chronic Migraine

Clinical trial NCT02614261 · COMPLETED

Trial details

NCT number: NCT02614261
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Migraine

Start date: 2015-11-30
Primary completion: 2017-03-16
Enrollment: 1117

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.